Five things for pharma marketers to know: Wednesday, August 17, 2016

Photo credit: Commons

1. A new study conducted by lobbying organization America's Health Insurance Plans found that nearly half (47%) of the usage of the 46 orphan drugs available between 2012 and 2014 was for non-orphan indications. In that time frame, the wholesale price of the 46 products increased by an average of 26%. (AHIP)

2. A new analysis says that clinical trials for GlaxoSmithKline's weight loss pill, Alli, significantly underestimated the drug's safety risks. Researchers said seven trials conducted by Roche downplayed its side effects. (Stat)

3. ViiV Healthcare has started two Phase-III trials for a two-drug HIV regimen that would simplify treatment for new patients. Most HIV treatment regimens consist of a three-drug cocktail. (PMLiVE)

4. Roche signed a deal with biotech Eleven Biotherapeutics to gain exclusive rights to an investigational treatment for diabetic macular oedema. The deal could be worth as much as $270 million. (PharmaTimes)

5. AstraZeneca will start a clinical-trial collaboration with Quintiles to assess the impact of mobile reminders for people with COPD to take their medicine. Patients in the trial will receive a Symbicort inhaler connected to the patient-support program BreatheMate. (MobiHealthNews)